DBV Technologies | DBVT - Net Income


DBV Technologies reported $-64.5M in Net Income for its fiscal quarter ending in September of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
Amarin USD -1.22M 6.51M Dec/2025
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
DBV Technologies USD -64.5M 16.9M Sep/2026
Galectin Therapeutics USD -12.37M 880K Jun/2024
Halozyme Therapeutics USD 247.05M 17.14M Sep/2026
Incyte USD -784.8M 1.37B Sep/2026
Insmed USD -13.24M 150.32M Jun/2026
Ionis Pharmaceuticals USD -87M 27.65M Sep/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
PTC Therapeutics USD 83.5M 86.3M Jun/2026
Sarepta Therapeutics USD -28.46M 23.57M Sep/2026
Ultragenyx Pharmaceutical USD -118M 26M Sep/2026
United Therapeutics USD 258.6M 74.4M Sep/2026